Ginkgo Bioworks

Ginkgo Bioworks, founded in 2009, is a prominent biotechnology company specializing in the development of a horizontal platform for cell programming. Operating from Boston, Massachusetts, the company leverages its expertise in synthetic biology and genetic engineering to enable customers to program cells for various applications. Its core mission revolves around making biology easier to engineer, thereby accelerating innovation across diverse sectors. The company's digital platform facilitates the design, development, and scaling of novel organisms and biological products, aiming to be a leader in the bioeconomy.

With a workforce ranging from 500 to 1,000 employees and operations spanning 3 locations, Ginkgo Bioworks focuses on delivering custom biological solutions. Their product offerings encompass horizontal platforms, organism engineering, and advanced cell programming services, underpinned by a strong foundation in biotech and synthetic biology. The company's approach allows for rapid iteration and development of biological designs, supporting clients in fields such as pharmaceuticals, agriculture, and consumer products. Meet Ginkgo Bioworks's team to understand the expertise driving these advancements.

Ginkgo Bioworks reported a revenue of $180.6M. The company has a history of significant funding rounds, indicating strong investor confidence in its innovative model. These investments support its ongoing research and development efforts in pushing the boundaries of biological engineering. The company's ticker symbol is NYSE: DNA. For a detailed overview of its financial performance and investment history, interested parties can Explore financial highlights. Ginkgo Bioworks aims to be a key partner in the bioeconomy, providing the tools and services necessary for next-generation biological products.